

***Fiscal Year 2024 Department of Defense Lung Cancer Research Program (LCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Career Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524LCRPCDA</p>	<p>Principal Investigator (PI)</p> <ul style="list-style-type: none"> • Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment (or equivalent). • Must not have received a Career Development Award previously from any program within the Congressionally Directed Medical Research Programs. • Must not have received more than \$300,000 in total direct costs for previous or concurrent lung cancer research as a PI of one or more federally or privately funded, non-mentored, peer-reviewed grants. <p>Mentor</p> <ul style="list-style-type: none"> • At or above the level of Associate Professor (or equivalent). • Must have a strong publication and funding record in lung cancer research. 	<ul style="list-style-type: none"> • Supports early-career, independent researchers to conduct research under the mentorship of an experienced lung cancer researcher. • Emphasis on research with high potential impact. • Clinical trials are not allowed. • Career development plan is required with appropriate mentor guidance. • Preliminary data are not required. • Relevance to military health is strongly encouraged. • <i>Pre-application Letter of Intent submission is required.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$375,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): May 28, 2024 5:00 p.m. Eastern time</p> <p>Application: June 17, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Concept Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524LCRPCA</p>	<p>Investigators at all academic levels.</p>	<ul style="list-style-type: none"> • Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer. • Emphasis on innovative concept or untested theory. • Research involving human subjects or specimens must be either exempt under Title 32, Code of Federal Regulations (CFR), Part 219, Section 104(d) (32 CFR 219.104[d]) or eligible for expedited review (21 CFR 56.110). • Clinical trials are not allowed. • Preliminary data are not required. • Relevance to military health is strongly encouraged. • Different application categories support research addressing specific Areas of Emphasis: <ul style="list-style-type: none"> ◦ <i>Care Delivery and Health Disparity category</i> must address one or more of the Disparities, Health Outcomes and Survivorship Areas of Emphasis. ◦ <i>Cancer Research Continuum category</i> must address at least one or more of the 10 cancer continuum-focused Areas of Emphasis. • <i>Pre-application Letter of Intent submission is required.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$120,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 1 year. 	<p>Pre-Application (Letter of Intent): May 28, 2024 5:00 p.m. Eastern time</p> <p>Application: June 17, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524LCRPIDA</p>	<p>Established Investigators</p> <p>Independent investigators at or above the level of an Assistant Professor (or equivalent).</p> <p>New Investigators</p> <p>Investigators must meet the following criteria at the application submission deadline date:</p> <ul style="list-style-type: none"> • Have not previously received an LCRP Idea Development Award. • Are within 10 years of first faculty appointment (or equivalent). 	<ul style="list-style-type: none"> • Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research. • Emphasis is on innovation and impact. • <i>New Investigator category</i> supports applicants early in their faculty appointments or in the process of developing independent research careers. • Clinical trials are not allowed. • Preliminary data are required. • Relevance to military health is strongly encouraged. • <i>Pre-application preproposal submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$525,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): May 28, 2024 5:00 p.m. Eastern time</p> <p>Application: August 7, 2024 11:59 p.m. Eastern time</p>
<p>Patient-Centered Outcomes and Survivorship Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524LCRPPCOSA</p>	<p>Independent investigators with a faculty-level appointment (or equivalent)</p>	<ul style="list-style-type: none"> • Supports high-reward studies that span the spectrum of behavioral health science, survivorship, and health outcomes/comparative effectiveness research, including quality of life, symptom and side effect management, resilience, co-morbid conditions and examining the physical, psychological, social, and economic effects of lung cancer. • Must address at least one area of emphasis in the Disparities or Health Outcomes/Survivorship categories. • Preliminary data are required. • Pilot clinical trials are allowed. • Relevance to military health is strongly encouraged. • <i>Pre-application Letter of Intent submission is required.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$650,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): July 17, 2024 5:00 p.m. Eastern time</p> <p>Application: August 7, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Translational Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524LCRPTRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> • Supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. • This mechanism is intended to fund a broad range of translational studies with two different funding levels. The following are general examples, although not all-inclusive, of the type of research projects that would be appropriate to propose under the current program announcement: <ul style="list-style-type: none"> Funding Level 1: <ul style="list-style-type: none"> ○ Advanced preclinical studies aimed at translating results from animal studies to applications with human samples/cohorts ○ Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug application submission ○ Correlative studies that are associated with an open/ongoing or completed clinical trial ○ Projects that develop endpoints for clinical trials Funding Level 2: <ul style="list-style-type: none"> ○ Pilot clinical trials where limited clinical testing (e.g., small sample size) of a novel intervention is necessary to inform the next step in the continuum of translational research ○ Patient research advocate involvement is encouraged • Preliminary lung cancer relevant data are required. • Relevance to military health is strongly encouraged. • <i>Pre-application preproposal submission is required; application submission is by invitation only.</i> 	<p>Funding Level 1</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$900,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. <p>Funding Level 2 – Clinical Trial Option</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,200,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): May 28, 2024 5:00 p.m. Eastern time</p> <p>Application: August 7, 2024 11:59 p.m. Eastern time</p>